Cargando…
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.
HLA phenotypes were characterized for 79 patients with metastatic renal cell carcinoma treated with interleukin 2 (IL-2). HLA-A32 was associated with a clinical response (P = 0.025). The frequency of HLA-A3 and/or A32 was higher among responders than non-responders (P = 0.008). Thus, these results s...
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group|1
1997
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063266/ https://www.ncbi.nlm.nih.gov/pubmed/9010039 |
| _version_ | 1782137300782678016 |
|---|---|
| author | Bain, C. Merrouche, Y. Puisieux, I. Blay, J. Y. Negrier, S. Bonadona, V. Lasset, C. Lanier, F. Duc, A. Gebuhrer, L. Philip, T. Favrot, M. C. |
| author_facet | Bain, C. Merrouche, Y. Puisieux, I. Blay, J. Y. Negrier, S. Bonadona, V. Lasset, C. Lanier, F. Duc, A. Gebuhrer, L. Philip, T. Favrot, M. C. |
| author_sort | Bain, C. |
| collection | PubMed |
| description | HLA phenotypes were characterized for 79 patients with metastatic renal cell carcinoma treated with interleukin 2 (IL-2). HLA-A32 was associated with a clinical response (P = 0.025). The frequency of HLA-A3 and/or A32 was higher among responders than non-responders (P = 0.008). Thus, these results suggest that, in vivo, IL-2 may enhance cellular-mediated immunity against a tumour antigen and that some MHC molecules are more efficient than others for endogenous tumour antigen presentation. |
| format | Text |
| id | pubmed-2063266 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 1997 |
| publisher | Nature Publishing Group|1 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-20632662009-09-10 Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. Bain, C. Merrouche, Y. Puisieux, I. Blay, J. Y. Negrier, S. Bonadona, V. Lasset, C. Lanier, F. Duc, A. Gebuhrer, L. Philip, T. Favrot, M. C. Br J Cancer Research Article HLA phenotypes were characterized for 79 patients with metastatic renal cell carcinoma treated with interleukin 2 (IL-2). HLA-A32 was associated with a clinical response (P = 0.025). The frequency of HLA-A3 and/or A32 was higher among responders than non-responders (P = 0.008). Thus, these results suggest that, in vivo, IL-2 may enhance cellular-mediated immunity against a tumour antigen and that some MHC molecules are more efficient than others for endogenous tumour antigen presentation. Nature Publishing Group|1 1997 /pmc/articles/PMC2063266/ /pubmed/9010039 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Research Article Bain, C. Merrouche, Y. Puisieux, I. Blay, J. Y. Negrier, S. Bonadona, V. Lasset, C. Lanier, F. Duc, A. Gebuhrer, L. Philip, T. Favrot, M. C. Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. |
| title | Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. |
| title_full | Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. |
| title_fullStr | Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. |
| title_full_unstemmed | Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. |
| title_short | Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. |
| title_sort | correlation between clinical response to interleukin 2 and hla phenotypes in patients with metastatic renal cell carcinoma. |
| topic | Research Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063266/ https://www.ncbi.nlm.nih.gov/pubmed/9010039 |
| work_keys_str_mv | AT bainc correlationbetweenclinicalresponsetointerleukin2andhlaphenotypesinpatientswithmetastaticrenalcellcarcinoma AT merrouchey correlationbetweenclinicalresponsetointerleukin2andhlaphenotypesinpatientswithmetastaticrenalcellcarcinoma AT puisieuxi correlationbetweenclinicalresponsetointerleukin2andhlaphenotypesinpatientswithmetastaticrenalcellcarcinoma AT blayjy correlationbetweenclinicalresponsetointerleukin2andhlaphenotypesinpatientswithmetastaticrenalcellcarcinoma AT negriers correlationbetweenclinicalresponsetointerleukin2andhlaphenotypesinpatientswithmetastaticrenalcellcarcinoma AT bonadonav correlationbetweenclinicalresponsetointerleukin2andhlaphenotypesinpatientswithmetastaticrenalcellcarcinoma AT lassetc correlationbetweenclinicalresponsetointerleukin2andhlaphenotypesinpatientswithmetastaticrenalcellcarcinoma AT lanierf correlationbetweenclinicalresponsetointerleukin2andhlaphenotypesinpatientswithmetastaticrenalcellcarcinoma AT duca correlationbetweenclinicalresponsetointerleukin2andhlaphenotypesinpatientswithmetastaticrenalcellcarcinoma AT gebuhrerl correlationbetweenclinicalresponsetointerleukin2andhlaphenotypesinpatientswithmetastaticrenalcellcarcinoma AT philipt correlationbetweenclinicalresponsetointerleukin2andhlaphenotypesinpatientswithmetastaticrenalcellcarcinoma AT favrotmc correlationbetweenclinicalresponsetointerleukin2andhlaphenotypesinpatientswithmetastaticrenalcellcarcinoma |